Abstract Background The clinical sequencing of cancer genomes to personalize therapy is becoming routine across the world. However, concerns over patient re-identification from these data lead to questions about how tightly access should be controlled. It is not thought to be possible to re-identify patients from somatic variant data. However, somatic variant detection pipelines can mistakenly identify germline variants as somatic ones, a process called “germline leakage”. The rate of germline leakage across different somatic variant detection pipelines is not well-understood, and it is uncertain whether or not somatic variant calls should be considered re-identifiable. To fill this gap, we qua...
Effective identification of genomic variations is a crucial step to understand the relationship betw...
Abstract Existing guidance regarding clinically informed germline testing for patients with cancer i...
We characterized two reference samples for NGS technologies: a human triple-negative breast cancer c...
Abstract Background The clinical sequencing of cancer...
BACKGROUND:The clinical sequencing of cancer genomes to personalize therapy is becoming routine acro...
International audienceA key constraint in genomic testing in oncology is that matched normal specime...
The rapid development of high-throughput sequencing technology provides a new chance to extend the s...
Abstract Background Cancer research to date has largely focused on somatically acquired genetic aber...
Cancer, which affects hundreds of thousands of people worldwide every year and costs billions in tre...
Somatic single nucleotide variants (SNVs) are mutations resulting from the substitution of a single ...
Technological innovation and increased affordability have contributed to the widespread adoption of ...
Technological innovation and increased affordability have contributed to the widespread adoption of ...
International audienceSingle-nucleotide variants (SNVs) are the most frequent genetic changes found ...
Cancer results from the progressive accumulation of genetic alterations that drive uncontrolled cell...
Germline alterations can have clinical implications for both cancer patients and their families. Bec...
Effective identification of genomic variations is a crucial step to understand the relationship betw...
Abstract Existing guidance regarding clinically informed germline testing for patients with cancer i...
We characterized two reference samples for NGS technologies: a human triple-negative breast cancer c...
Abstract Background The clinical sequencing of cancer...
BACKGROUND:The clinical sequencing of cancer genomes to personalize therapy is becoming routine acro...
International audienceA key constraint in genomic testing in oncology is that matched normal specime...
The rapid development of high-throughput sequencing technology provides a new chance to extend the s...
Abstract Background Cancer research to date has largely focused on somatically acquired genetic aber...
Cancer, which affects hundreds of thousands of people worldwide every year and costs billions in tre...
Somatic single nucleotide variants (SNVs) are mutations resulting from the substitution of a single ...
Technological innovation and increased affordability have contributed to the widespread adoption of ...
Technological innovation and increased affordability have contributed to the widespread adoption of ...
International audienceSingle-nucleotide variants (SNVs) are the most frequent genetic changes found ...
Cancer results from the progressive accumulation of genetic alterations that drive uncontrolled cell...
Germline alterations can have clinical implications for both cancer patients and their families. Bec...
Effective identification of genomic variations is a crucial step to understand the relationship betw...
Abstract Existing guidance regarding clinically informed germline testing for patients with cancer i...
We characterized two reference samples for NGS technologies: a human triple-negative breast cancer c...